Also known as: T2DM
Type 2 diabetes mellitus is a chronic hyperglycemic disorder caused by insulin resistance and progressive insulin secretory dysfunction. It accounts for the vast majority of diabetes cases globally.
New studies link GLP-1 drugs to eating disorders, erectile dysfunction and relationship changes, while Deloitte reports the drugs' market boom has lifted pharma R&D returns but created a concentration risk.
A cross-sectional study shows that type 2 diabetes and body mass index independently worsen arterial stiffness, with BMI having a greater impact. No synergy was found between the two risk factors.
A two-step FIB-4 plus VCTE approach effectively stratifies liver fibrosis and liver-related event risk in type 2 diabetes with MASLD. Prevalence of MASLD was 71.3% and significant fibrosis 21.1% in older outpatients.
A four-week dietary intervention reduced biological age in adults aged 65-75, with the strongest effect from an omnivorous high-carbohydrate diet. The Aging Cell study used 20 biomarkers. Longer-term research is needed.
Alnylam reported full-year 2025 profitability and $2.987 billion in global net product revenues, driven by U.S. approval and growth of AMVUTTRA. The company also outlined 2026 pipeline goals and additional HELIOS-B analyses for vutrisiran.
Two studies of older adults with type 2 diabetes linked diabetic retinal disease with higher dementia risk. DME and more severe diabetic retinopathy were associated with higher all-cause and vascular dementia risk, but not consistently with Alzheimer’s disease.
January and March 2026 drug pipeline updates included Phase 3 results, Fast Track designations and Priority Review decisions across multiple disease areas. Mavacamten, teplizumab-mzwv, anifrolumab, AXS-05, gedatolisib and AFTX-201 were among the programs with notable milestones.
A multicenter retrospective cohort study of 17 patients with type 2 diabetes and end-stage renal disease found injectable semaglutide was associated with descriptive changes in glycemic control and body weight. No cardiovascular deaths, nonfatal myocardial infarctions, or nonfatal strokes were observed during follow-up.
People with blood type B have a 28% higher risk of type 2 diabetes, while artificial sweetener consumption is linked to faster cognitive decline, particularly in younger adults and those with diabetes. The blood type finding comes from an umbrella review of 51 systematic reviews, while the sweetener study followed 12,772 Brazilian adults for eight years.
Oral semaglutide demonstrated significant improvements in multiple cardiometabolic risk factors in adults with type 2 diabetes at high cardiovascular risk. The SOUL trial analysis showed reductions in systolic blood pressure, cholesterol, triglycerides, HbA1c, and body weight compared to placebo. These benefits were observed as early as 13 weeks and contributed to a 14% reduction in major adverse cardiovascular events.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07775664 |
Huangqi Gegen Decoction for Endothelial Function in Type 2 Diabetes at Very High ASCVD Risk |
ACTIVE_NOT_RECRUITING | NA |
| NCT07773467 |
Systemic Immune-Inflammation Index and Platelet Parameters in Diabetic Kidney Disease |
NOT_YET_RECRUITING | |
| NCT07768280 |
Efficacy and Safety of Hebenrun in Patients With Type 2 Diabetes |
NOT_YET_RECRUITING | NA |
| NCT07757399 |
The Therapeutic Effects of Ceylon Cinnamon Supplementation and a Self-Efficacy Educational Program on Glycemic Control, Lipid Profiles, and Pain in Type 2 Diabetes Mellitus With Painful Diabetic Peripheral Neuropathy |
NOT_YET_RECRUITING | NA |
| NCT07755150 |
A Study to Evaluate the Efficacy and Safety of DA-302168S Tablets in Subjects With Type 2 Diabetes |
NOT_YET_RECRUITING | PHASE2 |
| NCT07743450 |
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes |
RECRUITING | PHASE3 |
| NCT07729553 |
Vitamin D Status and Lipid Profile in Obese Adults With Type 2 Diabetes |
NOT_YET_RECRUITING | |
| NCT07723820 |
Glycemic Velocity and Early Retinal Microvascular Change With GLP-1RA Versus SGLT2i Initiation in Type 2 Diabetes (GLIDE) |
NOT_YET_RECRUITING | |
| NCT07717697 |
Finerenone for the Treatment of Type 2 Diabetes-Related Kidney Disease: Efficacy Observation and Related Factor Analysis |
NOT_YET_RECRUITING | |
| NCT07711171 |
Efficacy and Safety of Canagliflozin in the Treatment of Type 2 Diabetes With Mild Cognitive Impairment |
RECRUITING | PHASE4 |
